BackgroundCheck.run
Search For

Jiali M Li, 54Santee, CA

Known as:
Li Jiali

Jiali Li Phones & Addresses

Santee, CA   

4085 Nobel Dr, San Diego, CA 92122    858-4531521   

Wynnewood, PA   

6314 Chasewood Dr, Jupiter, FL 33458    561-7689368   

Get Report
Control this profile

Mentions for Jiali M Li

Career records & work history

Medicine Doctors

Jiali Li

Specialties:
Hematology/Oncology
Work:
Valley Medical Oncology CnsltEl Camino Hospital Cancer Center
2505 Hospital Dr, Mountain View, CA 94040
650-9888338 (phone) 650-9624594 (fax)
Site
Education:
Medical School
Tianjin Med Univ, Tianjin City, Tianjin, China
Graduated: 1995
Procedures:
Chemotherapy
Conditions:
Iron Deficiency Anemia, Malignant Neoplasm of Female Breast, Multiple Myeloma, Non-Hodgkin's Lymphoma, Anemia, Breast Neoplasm, Malignant, Leukemia, Sickle-Cell Disease, Vitamin B12 Deficiency Anemia
Languages:
English, Russian, Spanish
Description:
Dr. Li graduated from the Tianjin Med Univ, Tianjin City, Tianjin, China in 1995. She works in Mountain View, CA and specializes in Hematology/Oncology. Dr. Li is affiliated with El Camino Hospital, Good Samaritan Hospital, Sequoia Hospital and Stanford Hospital.

Jiali Li resumes & CV records

Resumes

Jiali Li Photo 20

Research Scientist

Location:
130 Scripps Way, Jupiter, FL 33458
Industry:
Research
Work:
The Scripps Florida Research Institute since Aug 2006
research associate Scripps Research Institute since Jan 2006
Research Associate The Scripps Research Institute Jun 2004 - Aug 2006
Research Associate 2004-2006 Jun 2004 - Aug 2006
Research Associate National Institute of Virology, China CDC Jun 2002 - Jun 2004
Postdoc Anesthesiologist in JILIN Jan 1993 - Jan 1996
doctor
Education:
Jilin University 1999 - 2002
Ph.D, ImmunologyThesis title: engineering antibody to human IL-2R Beihua University 1996 - 1999
Master, Clinical ImmunologyThesis title:Screening cytomegalovirus infection in pregnant women Beihua University 1988 - 1993
M.D., Medicine School of Medicine, BEIHUA University
Medical Degree (M.D School of Medicine, BEIHUA University
M.S, Clinical ImmunologyThesis Title: Screening cytomegalovirus infection in pregnant women Supervisor: Professor Ruolun Li School of Medicine, JILIN University
Ph.D, ImmunologyThesis Title: Engineering antibody to human IL-2R Supervisor: Professor Xun Zhu
Skills:
Facs Analysis, Immunoassays, High Throughput Screening, Elisa and Elispot, Antibodies, Cell, Virology, Cell Culture, Molecular Biology, Cell Fusion, Immunohistochemistry, Cell Cloning, Cell Based Assays, Live Imaging, Protein Expression, Primary Neuron Culture, Protein Biochemistry, Fluorescence Microscopy, Mouse Manipulation
Languages:
Mandarin
Jiali Li Photo 21

Jiali Li

Location:
Los Angeles, CA
Work:
Advin Biotech
Education:
Uc Santa Barbara
Jiali Li Photo 22

Research Scientist

Location:
San Diego, CA
Industry:
Biotechnology
Work:
X-Ceptor 2000 - 2004
Research Scientist Exelixis 2000 - 2004
Research Scientist
Jiali Li Photo 23

Jiali Li

Location:
San Diego, CA
Jiali Li Photo 24

Jiali Li

Publications & IP owners

Us Patents

Combinations

US Patent:
2023008, Mar 23, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757486
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Jianhui Ma - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/437
A61K 31/519
A61K 45/06
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023006, Mar 2, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757483
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/519
A61K 31/5383
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor, and a SERD or SERM inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023005, Feb 23, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757485
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Jianhui Ma - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/4353
A61K 31/519
A61K 31/506
A61K 31/4439
A61K 31/55
A61K 31/513
A61K 31/565
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and another inhibitor (such as a CDK4/6 inhibitor, a selective aromatase inhibitor, a non-selective aromatase inhibitor, a mTOR inhibitor, a PI3K inhibitor, an ERK or a MEK inhibitor, AKT inhibitor, a BET inhibitor and an Aurora inhibitor), along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023005, Feb 23, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757514
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Jianhui Ma - San Diego CA, US
Hooman Izadi - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Joseph Robert Pinchman - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/437
A61K 31/438
A61K 31/5377
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023005, Feb 23, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757530
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Hooman Izadi - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Joseph Robert Pinchman - San Diego CA, US
Brant Clayton Boren - Escondido CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/519
A61K 31/437
A61K 31/5377
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a Bcl-2 inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023004, Feb 9, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757511
Inventors:
- San Diego CA, US
Jianhui Ma - San Diego CA, US
Jiali Li - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/437
A61K 31/519
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a SERD inhibitor and a WEE1 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Combinations

US Patent:
2023000, Jan 12, 2023
Filed:
Dec 16, 2020
Appl. No.:
17/757493
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Hooman Izadi - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Brant Clayton Boren - San Diego CA, US
Joseph Robert Pinchman - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - Santa Monica CA, US
International Classification:
A61K 31/519
A61K 31/635
A61K 31/496
A61P 35/00
Abstract:
Disclosed herein are combinations of compounds for treating a disease or condition, such as cancer. A combination of compounds for treating a disease or condition can include a WEE1 inhibitor and a Bcl-2 inhibitor, along with pharmaceutically acceptable salts of any of the foregoing.

Estrogen Receptor Modulators For Treating Mutants

US Patent:
2021003, Feb 11, 2021
Filed:
Aug 4, 2020
Appl. No.:
16/985004
Inventors:
- San Diego CA, US
Jiali Li - San Diego CA, US
Jianhui Ma - San Diego CA, US
Sayee Gajanan Hegde - San Diego CA, US
Peter Qinhua Huang - San Diego CA, US
Kevin Duane Bunker - Escondido CA, US
Fernando Donate - San Diego US, US
International Classification:
A61K 31/437
A61P 35/00
Abstract:
Uses and methods that include an effective amount of Compound (A), or a pharmaceutically acceptable salt thereof, are described herein for treating breast cancer in a subject in need thereof, wherein the breast cancer has at least one point mutation within the Estrogen Receptor 1 (ESR1) that encodes Estrogen receptor alpha (ERĪ±).

Possible Relatives

Cynthia M Li  David Li  Dawei Li  Dayu W Li  De Li  Dean Li  Jiali Liu  Jiali Chen 

NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.